SLNO

Soleno Therapeutics, Inc. (SLNO) | Rumor.io

Soleno Therapeutics

SLNO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)66%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SLNO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

May 18

Neurocrine Biosciences has completed its acquisition of Soleno Therapeutics (SLNO) for $2.9 billion, valuing SLNO at $53.00 per share.
SLNO shares have been delisted from the board, marking the end of Soleno Therapeutics as an independent publicly traded company.
The acquisition is expected to expand Neurocrine's rare disease portfolio, with VYKAT XR becoming the first and only approved treatment for hyperphagia in Prader-Willi syndrome.

Generated by AI

Sentiment

Of the messages about SLNO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -61.54	71.3% -8.07
Bearish	—	—	100% +61.54	28.7% +8.07

Bullish· Apr 7

Soleno Therapeutics, Inc. (SLNO) has been added to a portfolio at attractive levels, with the investor still holding long-term expectations.
The company's acquisition by Neurocrine Biosciences for $2.9 billion is a major catalyst, validating the imminent clinical trial success and signaling a major inflection point for its rare-disease portfolio.
International Biotechnology Trust is bullish on SLNO, holding it as its top holding (6% of NAV), and expects sector rotation to drive future biotech M&A opportunities.

Bearish· Apr 6

The asset's price may be impacted by a potential acquisition, with the company being bought out for $53/share cash.
The asset's value may be overestimated, with one commenter stating that the company is not worth more than $OMER and highlighting the significant revenue generated by one of its drugs.
The asset's recent performance may be due to a short squeeze, with one commenter suggesting that the company's recent price increase was triggered by a short thesis.

Generated by AI

Topics

Of the messages about SLNO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	1.26%
Macro	—	—	14.29%	26.88%
Earnings	—	—	85.71%	5.22%
Controversies	—	—	0%	0.98%
Announcements	—	—	0%	32.85%
Analysts	—	—	0%	32.8%

Earnings· Aug 8

Soleno Therapeutics, Inc. ($SLNO) earnings are awaited.

Announcements· Apr 7

Soleno Therapeutics, Inc. (SLNO) has withdrawn its European marketing authorization application for VIOKAT, a treatment for Prader-Willi syndrome.
SLNO will be acquired by Neurocrine Biosciences (NBIX) in a $2.9B all-cash deal, with a price of $53.00 per share.
The acquisition is expected to expand Neurocrine's rare-disease portfolio and has led to a significant surge in SLNO's stock price.

Technical Analysis· Apr 6

$SLNO decisively breaches $44.38 resistance on massive volume, confirming powerful momentum and a 32% surge.
The breakout is fueled by the Neurocrine buyout news, with a $2.9B acquisition catalyst providing fundamental support.
Technical target now projects toward $72.97, supported by the acquisition news and institutional conviction.

Generated by AI

Community

Of the messages about SLNO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	45.83%	62.87%
Newcomers	—	—	54.17%	37.13%

Regulars· Apr 6

$SLNO is reportedly nearing a $2.5bn-plus deal to be acquired by Neurocrine Biosciences, with the acquisition price potentially exceeding $2.9B.
The regulars are optimistic about the potential for a second bidder to emerge in the deal, citing the company's high profitability and growing attractiveness.
The acquisition price is seen as a relatively low buyout premium, with some participants questioning whether anyone will emerge from the deal a winner, long or short.

Newcomers· Apr 7

The acquisition of Soleno Therapeutics by Neurocrine Biosciences is a significant event, with the deal valued at $2.7 billion and expected to close in July 2026.
Newcomers to the biotech world are focusing on the potential benefits of the acquisition, including improved revenue growth and a stronger risk profile for Neurocrine Biosciences.
Some investors are questioning the acquisition, citing concerns that Soleno Therapeutics may have sold low due to regulatory issues, and that Neurocrine Biosciences may be taking on debt without a clear plan for growth.

Generated by AI

Also Discussed

Investors talking about SLNO also mention

#	Name	Attention
1	Mineralys Therapeutics, Inc.MLYS	0%+0
2	LBPH - Longboard Pharmaceuticals, Inc.	——
3	Rhythm Pharmaceuticals, Inc.RYTM	0%0
4	Mirum Pharmaceuticals, Inc.MIRM	0%0
5	Praxis Precision Medicines, Inc.PRAX	0%0
6	FZT - FAST Acquisition Corp. II	——
7	Akari Therapeutics Plc ADRAKTX	0%0
8	MURF - Murphy Canyon Acquisition Corp.	——
9	FRBN - Forbion European Acquisition Corp.	——
10	AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETFSIXD	0%0